Noah L. Rosenberg

CIK: 0001579649

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRCA

Verrica Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VRCA
Verrica Pharmaceuticals Inc.
Aug 18, 2026
Purchase(P)
Direct
2K shares at avg. $4.92$10K
VRCA
Verrica Pharmaceuticals Inc.
Aug 17, 2026
Purchase(P)
Direct
4.2K shares at avg. $4.91$21K
VRCA
Verrica Pharmaceuticals Inc.
Jun 5, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
233.8K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 25, 2025
Purchase(P)
Direct
2.4K shares at avg. $4.24$10K
VRCA
Verrica Pharmaceuticals Inc.
Mar 24, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
325K shares-

		Type	Shares	Price		Ownership
Aug 18, 2026	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	2,030	$4.92	$9,988	Direct
Aug 17, 2026	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	4,200	$4.91	$20,622	Direct
Jun 5, 2026	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	233,840	-	-	Direct
Nov 25, 2025	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	2,357	$4.24	$10,000	Direct
Mar 24, 2025	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	325,000	-	-	Direct

1-5 of 5 transactions

About Rosenberg Noah L.

Rosenberg Noah L. (SEC CIK 0001579649) files insider reports with the SEC as CMO of Verrica Pharmaceuticals Inc. (VRCA).

Signal8 holds 5 ownership filings by Rosenberg Noah L. (1 Form 3, 4 Form 4), filed between Mar 26, 2025 and Aug 18, 2026. Those filings report 5 transactions, from Mar 24, 2025 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rosenberg Noah L.'s filings is in WEST CHESTER, PA.

Recent filings by Rosenberg Noah L.

Aug 18, 2026: Open-market purchase of VRCA shares (Form 4, code P).
Aug 17, 2026: Open-market purchase of VRCA shares (Form 4, code P).
Jun 5, 2026: Grant or award of VRCA derivative securities (Form 4, code A).
Nov 25, 2025: Open-market purchase of VRCA shares (Form 4, code P).
Mar 24, 2025: Grant or award of VRCA derivative securities (Form 4, code A).

Other insiders filing for Verrica Pharmaceuticals Inc. (VRCA)

Zawitz David, Chief Operating Officer
Rieger Jayson, CEO and President
Kirby John J., Interim CFO
Eichenfield Lawrence, Director
Nguyen Diem, Director
PRYGOCKI MARK A SR, Director

How to read Form 4 transaction codes